
Currently out of the existing stock ratings of Mason Carrico, 83 are a BUY (87.37%), 12 are a HOLD (12.63%).
Analyst Mason Carrico, currently employed at STEPHENS, has had 64.12% of price targets met with an average potential upside of 33.38%, reached in 307 days on average.
Mason Carrico has documented 154 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on MYGN, .
Analyst best performing recommendations are on CTKB (CYTEK BIOSCIENCES).
The best stock recommendation documented was for CTKB (CYTEK BIOSCIENCES) on 12/13/2023. The price target of $9 was fulfilled within 2 days with a profit of $0.98 (12.22%), with a performance score of 61.1.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 09-Nov-2020
$40
$6.21 (18.38%)
$35
10 days ago
(06-Nov-2026)
9/10 (90%)
$7.48 (23.00%)
371
Buy Since 19-Aug-2019
$44
$10.21 (30.22%)
$50
3 months 13 days ago
(03-Aug-2026)
9/11 (81.82%)
$13.61 (44.78%)
232
Buy Since 21-May-2020
$40
$6.21 (18.38%)
$84
4 months 22 days ago
(25-Jun-2026)
7/8 (87.5%)
$17.09 (74.60%)
47
Buy Since 19-Aug-2019
$40
$6.21 (18.38%)
$40
6 months 3 days ago
(13-May-2026)
11/15 (73.33%)
$21.85 (120.39%)
396
Buy Since 19-Aug-2019
$43
$9.21 (27.26%)
$44
6 months 9 days ago
(07-May-2026)
16/24 (66.67%)
$23.76 (123.49%)
358